Harrow Inc HROW

$29.36 -1.16 (-3.80%)

Valuation

Market cap
1,100,647,000
Revenue TTM
$272,300,000
Net income TTM
$-5,140,000
PE ratio
0.00
Forward PE
—
Profit margin
-1.89%
Debt to equity
19.69

Trading

Volume
1,352,300
Avg volume
573,306
Day's range
$27.00 – $30.90
Shares out
37,488,000
Stochastic %K
49%
Beta
0.19
Analysts
Strong Sell
Price target
$63.00

Price

Company profile

Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEV...

Show more

Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE, as well as BYQLOVI; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; BYOOVIZ, a LUCENTIS biosimilar indicated for the treatment of patients with Neovascular (Wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), and myopic choroidal neovascularization (mCNV); VIGAMOX, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; OPUVIZ, an EYLEA biosimilar indicated for the treatment of patients with Wet AMD, macular edema following RVO, diabetic macular edema (DME), and diabetic retinopathy (DR); MAXIDEX and FLAREX, a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe and the eye; TRIESENCE, a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and NATACYN, a sterile, antifungal drug for the treatment of fungal blepharitis, conjunctivitis, and keratitis. In addition, it offers TOBRADEX ST, a tobramycin and dexamethasone ophthalmic suspension; VERKAZIA cyclosporine ophthalmic emulsion; NEVANAC, a non-steroidal, anti-inflammatory eye drop; and FRESHKOTE preservative free (PF) is a lubricant eye drop. The company was formerly known as Harrow Health, Inc. and changed its name to Harrow, Inc. in September 2023. Harrow, Inc. was founded in 1998 and is headquartered in Nashville, Tennessee.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Phone
615 733 4730
Website
https://www.harrow.com
Address
1A Burton Hills Boulevard, Suite 200, Nashville, United States

Latest news

Stocktwits

Fullback Oct 12, 6:59 AM
$HROW
0 replies
Finnish_boy Oct 11, 4:30 PM
$HROW Remember always valuation. P/S is now only 4.5🤯 Buying now is already crazy R/R within 1-2 years. Stock can go lower, maybe $22-$24 if Q3 revenue 95M or lower and they adjust full year guidance lower. But volatility is not any risk, you have no need to sell. Wait 2027 and 2028 and sell over $100 levels🤑waiting game
0 replies
Finnish_boy Oct 11, 1:17 PM
$HROW Q3 seasonally weaker than q2 for iheezo? Q4 25, Q1 and Q2 numbers were all misleading due to inventory stocking, end of pass through reimbursement, and launch 5-pack iheezo? I assumed higher iheezo revenue in Q3 than in Q2. Is there any chance that the iheezo data is now very misleading, 5-pack iheezo? Net pricing better in Q3 than in Q2. Interesting to see the iheezo revenue
1 replies
Finnish_boy Oct 10, 11:09 AM
$HROW And execution has not been perfect, mgt told itself that they have made mistakes, Triesence strategy and inventory problems with Vevye and some others. But my point that vevye amazing drug but you can do nothing if no coverage. Like you have to wait for more coverage. And iheezo is great drug but resistance to change among doctors very big. Like you dont need iheezo. Old drugs are enough. But iheezo is better and they will switch into it little by little. Again takes time. They will do more M&As, that's one reason now why i own the stock. They are real player. Biggest reason is that i think current portfolio can have 1B run rate by Q4 2028.
2 replies
Finnish_boy Oct 10, 8:05 AM
$HROW They are now attractive partner. More M&As ahead. It's big deal when others want to partner with Harrow. It' remarkable how they build the portfolio from zero and being now very serious player. Biosimilars, Byqlovi, Tyrvaya, what drug is next? Near-term revenue is pushed back. E.g 2028 is big year for Vevye if another major commerical coverage wins. Iheezo retina-label would be major boost. I think biggest problem has been that markets have thought that the drugs are better than they really are and one reason for that too optimistic mgt. The execution has been maybe great, but mgt and investors wanted more. E.g dry eye drugs need more coverage to be blockbuster and still not so profitable (Miebo, vevye, tryptyr). And it takes time. 2027: growing 2028: all cylinders firing 2029: all cylinders firing 2030+: keeping the momentum
0 replies
Finnish_boy Oct 9, 11:38 PM
$HROW will huge runner in 2027. Q3 revenue likely under 100M, but valuation ridiculous so hard to predict price action. My near-term bull thesis didnt work out bc i assumed much higher VEVYE ASP. Long-term thesis valid and stock going to $100 in 2027/2028 very likely. And $150-$200 by 2030 very possible. My all positions failed this year. I cant believe but my YTD is -40% and indexes ATH. No words. What makes it harder i still think that i made good choices so that is very dangerous when you think you are doing right but results are very negative. HROW will be fine. Not sure about my portfolio😂i will be shutting it down next year likely😂
4 replies
Fullback Oct 9, 10:56 PM
$HROW
0 replies
Dbarnyard Oct 9, 4:41 PM
$HROW Not surprised Opaleye is done with how much money they made on ETON. They also made a bunch here in the early days, even with this being a total pig as of late, so not surprised they are dumping this as well.
0 replies